Loading stock data…
Trevi Therapeutics (TRVI)
$18.58+0.43 (+2.37%)
Market OpenUpdated 3:03 PM EDT
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $18.58 with a market capitalization of $2.0B. Wall Street consensus targets $23.90 (10 analysts), implying a +28.6% move over the next 12 months. The stock is currently near its 52-week high of $18.59, remaining 53.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.91M↓ | -$10.22M↑ | -$13.92M↓ | -$13.72M↓ | -$11.47M |
| Net Income | -$13.19M↓ | -$8.32M↑ | -$11.80M↑ | -$12.30M↓ | -$10.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.50%
Volume
Today's trading volume
1.63M
Recent News
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Trevi Therapeutics, Inc.'s Q1 2026 earnings call
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030
Trevi Therapeutics recently reported a first‑quarter 2026 net loss of US$13.19 million, broadly flat on a per‑share basis, while outlining plans to advance multiple chronic cough trials for its lead drug Haduvio. Alongside this, the company raised approximately US$162 million in a follow‑on offering, extending its cash runway into 2030 and supporting expanded clinical development and intellectual property efforts. We’ll now examine how the extended cash runway to 2030 reshapes Trevi’s...
Trevi Therapeutics Q1 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres